Research graph
References from Mesenchymal Stem Cells as a Therapeutic Treatment for Osteogenesis Imperfecta: Current Understanding Through Clinical Trials. Local targets link to admitted publications; unresolved targets remain external evidence.
Current overview of osteogenesis imperfecta
10.3390/medicina57050464 · 2021 · External reference
Update on the genetics of osteogenesis imperfecta
10.1007/s00223-024-01266-5 · 2024 · External reference
10.1002/ctm2.265
10.1002/ctm2.265 · External reference
Osteogenesis imperfecta: mechanisms and signaling pathways connecting classical and rare OI types
10.1210/endrev/bnab017 · 2022 · External reference
Unresolved reference
External reference
10.1002/ajmg.a.63935
10.1002/ajmg.a.63935 · External reference
Osteogenesis imperfecta
10.1038/nrdp.2017.52 · 2017 · External reference
Osteogenesis imperfecta: pathogenesis, classification and treatment
10.1297/cpe.2025-0009 · 2025 · External reference
Type 1 collagen: synthesis, structure and key functions in bone mineralization
10.1016/j.diff.2024.100757 · 2024 · External reference
COL1A1 and COL1A2 variants in Ehlers-Danlos syndrome phenotypes and COL1-related overlap disorder
10.1002/ajmg.c.32038 · 2023 · External reference
10.1371/journal.pone.0309801
10.1371/journal.pone.0309801 · External reference
The role of mitochondrial homeostasis in mesenchymal stem cell therapy-potential implications in the treatment of osteogenesis imperfecta
10.3390/ph17101297 · 2024 · External reference
10.1089/hum.2024.191
10.1089/hum.2024.191 · External reference
Osteogenesis imperfecta: advancements in genetics and treatment
10.1097/mop.0000000000000813 · 2019 · External reference
Bisphosphonates for the prevention of fractures in osteogenesis imperfecta: meta-analysis of placebo-controlled trials
10.1002/jbmr.2410 · 2015 · External reference
Approach to the patient: pharmacological therapies for fracture risk reduction in adults with osteogenesis imperfecta
10.1210/clinem/dgad035 · 2023 · External reference
Mesenchymal stem cells
10.3727/096368910x · 2011 · External reference
Mesenchymal stem cells in the treatment of osteogenesis imperfecta
10.1186/s13619-022-00146-3 · 2023 · External reference
10.1186/s12915-015-0212-7
10.1186/s12915-015-0212-7 · External reference
Advantages of mesenchymal stem cell over the other stem cells
10.1016/j.acthis.2023.152041 · 2023 · External reference
Classification of osteogenesis imperfecta revisited
10.1016/j.ejmg.2009.10.007 · 2010 · External reference
Osteogenesis imperfecta
10.1016/j.berh.2007.12.012 · 2008 · External reference
Unresolved reference
External reference
Perinatal lethal type II osteogenesis imperfecta: a case report
10.11604/pamj.2015.21.11.6834 · 2015 · External reference
Imaging in osteogenesis imperfecta: where we are and where we are going
10.1016/j.ejmg.2024.104926 · 2024 · External reference
Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta
10.1038/6529 · 1999 · External reference
Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone
10.1073/pnas.132252399 · 2002 · External reference
Gene targeting in stem cells from individuals with osteogenesis imperfecta
10.1126/science.1088757 · 2004 · External reference
Intrauterine transplantation of human fetal mesenchymal stem cells from first-trimester blood repairs bone and reduces fractures in osteogenesis imperfecta mice
10.1182/blood-2007-08-105809 · 2008 · External reference
Hydroxyproline: a potential biochemical marker and its role in the pathogenesis of different diseases
10.2174/1389203717666151201192247 · 2016 · External reference
Pre- and postnatal transplantation of fetal mesenchymal stem cells in osteogenesis imperfecta: a two-center experience
10.5966/sctm.2013-0090 · 2014 · External reference
10.1136/bmjopen-2023-079767
10.1136/bmjopen-2023-079767 · External reference
Ethical and safety issues of stem cell-based therapy
10.7150/ijms.21666 · 2018 · External reference
10.1002/ajmg.a.63935
10.1002/ajmg.a.63935 · ExternalCitation · doi-reference
COL1A1 and COL1A2 variants in Ehlers-Danlos syndrome phenotypes and COL1-related overlap disorder
10.1002/ajmg.c.32038 · ExternalCitation · doi-reference
10.1002/ctm2.265
10.1002/ctm2.265 · ExternalCitation · doi-reference
Bisphosphonates for the prevention of fractures in osteogenesis imperfecta: meta-analysis of placebo-controlled trials
10.1002/jbmr.2410 · ExternalCitation · doi-reference
Update on the genetics of osteogenesis imperfecta
10.1007/s00223-024-01266-5 · ExternalCitation · doi-reference
Advantages of mesenchymal stem cell over the other stem cells
10.1016/j.acthis.2023.152041 · ExternalCitation · doi-reference
Osteogenesis imperfecta
10.1016/j.berh.2007.12.012 · ExternalCitation · doi-reference
Type 1 collagen: synthesis, structure and key functions in bone mineralization
10.1016/j.diff.2024.100757 · ExternalCitation · doi-reference
Classification of osteogenesis imperfecta revisited
10.1016/j.ejmg.2009.10.007 · ExternalCitation · doi-reference
Imaging in osteogenesis imperfecta: where we are and where we are going
10.1016/j.ejmg.2024.104926 · ExternalCitation · doi-reference
Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta
10.1038/6529 · ExternalCitation · doi-reference
Osteogenesis imperfecta
10.1038/nrdp.2017.52 · ExternalCitation · doi-reference
Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone
10.1073/pnas.132252399 · ExternalCitation · doi-reference
10.1089/hum.2024.191
10.1089/hum.2024.191 · ExternalCitation · doi-reference
Osteogenesis imperfecta: advancements in genetics and treatment
10.1097/mop.0000000000000813 · ExternalCitation · doi-reference
Gene targeting in stem cells from individuals with osteogenesis imperfecta
10.1126/science.1088757 · ExternalCitation · doi-reference
10.1136/bmjopen-2023-079767
10.1136/bmjopen-2023-079767 · ExternalCitation · doi-reference
Perinatal lethal type II osteogenesis imperfecta: a case report
10.11604/pamj.2015.21.11.6834 · ExternalCitation · doi-reference
Intrauterine transplantation of human fetal mesenchymal stem cells from first-trimester blood repairs bone and reduces fractures in osteogenesis imperfecta mice
10.1182/blood-2007-08-105809 · ExternalCitation · doi-reference
10.1186/s12915-015-0212-7
10.1186/s12915-015-0212-7 · ExternalCitation · doi-reference
Mesenchymal stem cells in the treatment of osteogenesis imperfecta
10.1186/s13619-022-00146-3 · ExternalCitation · doi-reference
Approach to the patient: pharmacological therapies for fracture risk reduction in adults with osteogenesis imperfecta
10.1210/clinem/dgad035 · ExternalCitation · doi-reference
Osteogenesis imperfecta: mechanisms and signaling pathways connecting classical and rare OI types
10.1210/endrev/bnab017 · ExternalCitation · doi-reference
Osteogenesis imperfecta: pathogenesis, classification and treatment
10.1297/cpe.2025-0009 · ExternalCitation · doi-reference
10.1371/journal.pone.0309801
10.1371/journal.pone.0309801 · ExternalCitation · doi-reference
Hydroxyproline: a potential biochemical marker and its role in the pathogenesis of different diseases
10.2174/1389203717666151201192247 · ExternalCitation · doi-reference
Current overview of osteogenesis imperfecta
10.3390/medicina57050464 · ExternalCitation · doi-reference
The role of mitochondrial homeostasis in mesenchymal stem cell therapy-potential implications in the treatment of osteogenesis imperfecta
10.3390/ph17101297 · ExternalCitation · doi-reference
Mesenchymal stem cells
10.3727/096368910x · ExternalCitation · doi-reference
Pre- and postnatal transplantation of fetal mesenchymal stem cells in osteogenesis imperfecta: a two-center experience
10.5966/sctm.2013-0090 · ExternalCitation · doi-reference
Ethical and safety issues of stem cell-based therapy
10.7150/ijms.21666 · ExternalCitation · doi-reference
